318,051 Shares in Epizyme Inc (EPZM) Purchased by Marshall Wace LLP
Marshall Wace LLP bought a new stake in Epizyme Inc (NASDAQ:EPZM) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 318,051 shares of the biopharmaceutical company’s stock, valued at approximately $3,371,000. Marshall Wace LLP owned about 0.40% of Epizyme as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Alps Advisors Inc. increased its stake in Epizyme by 22.0% in the third quarter. Alps Advisors Inc. now owns 122,992 shares of the biopharmaceutical company’s stock valued at $1,304,000 after acquiring an additional 22,150 shares during the last quarter. Northern Trust Corp increased its stake in Epizyme by 12.1% in the second quarter. Northern Trust Corp now owns 651,179 shares of the biopharmaceutical company’s stock valued at $8,823,000 after acquiring an additional 70,281 shares during the last quarter. Sofinnova Ventures Inc purchased a new stake in Epizyme during the third quarter valued at about $3,087,000. BB&T Securities LLC boosted its position in Epizyme by 45.5% during the second quarter. BB&T Securities LLC now owns 16,000 shares of the biopharmaceutical company’s stock valued at $216,000 after buying an additional 5,000 shares during the period. Finally, Spark Investment Management LLC purchased a new stake in Epizyme during the second quarter valued at about $597,000. 73.27% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ EPZM opened at $5.88 on Friday. Epizyme Inc has a 12-month low of $5.81 and a 12-month high of $21.40. The stock has a market cap of $465.51 million, a price-to-earnings ratio of -2.70 and a beta of 2.08.
Several analysts have issued reports on EPZM shares. SunTrust Banks upped their price target on shares of Epizyme to $25.00 and gave the company a “buy” rating in a research report on Tuesday, September 25th. Oppenheimer set a $27.00 price target on shares of Epizyme and gave the company a “buy” rating in a research report on Friday, November 2nd. Roth Capital set a $18.00 price target on shares of Epizyme and gave the company a “buy” rating in a research report on Monday, October 22nd. BidaskClub lowered shares of Epizyme from a “hold” rating to a “sell” rating in a research report on Friday, October 5th. Finally, Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $8.25 price target for the company in a research report on Tuesday, December 4th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $19.73.
In other news, Director David M. Mott bought 416,667 shares of the company’s stock in a transaction dated Friday, October 5th. The stock was bought at an average cost of $9.00 per share, for a total transaction of $3,750,003.00. Following the completion of the acquisition, the director now owns 12,088 shares in the company, valued at approximately $108,792. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 21.50% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “318,051 Shares in Epizyme Inc (EPZM) Purchased by Marshall Wace LLP” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2018/12/16/318051-shares-in-epizyme-inc-epzm-purchased-by-marshall-wace-llp.html.
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Featured Story: Conference Calls
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.